Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline - Wikidata - awgldk - TriplyDB

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

http://www.wikidata.org/entity/Q26853619

about

Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.Gambogic acid inhibits growth, induces apoptosis, and overcomes drug resistance in human colorectal cancer cells A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22.Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1-2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial.Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.

P2860

Q35786472-3BB79062-D129-48AC-9167-AD7375C433E8 Q36140567-ECB068E9-3222-4A2C-8537-9C5E35EB2144 Q36234011-351CBDFE-6F12-4C7D-A2DE-0C90957FE586 Q37709879-B25B0BC8-A3B6-4979-A71C-92C84580D6B9 Q41706289-685BB9B3-1D52-4A56-831B-00F2F80A8E0A Q48163403-2834435A-5D75-4677-9797-5AF2DF9B1BE3 Q52595390-41FD59CF-C19F-4D8F-8D46-E91EA42E7BED

P2860

Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline

http://www.wikidata.org/entity/Q26853619

description

2015 nî lūn-bûn

@nan

2015 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի մարտին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@ast

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@en

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@nl

type

label

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@ast

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@en

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@nl

prefLabel

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@ast

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@en

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@nl

P1433

Q26853619-31839BE7-AAE5-4BC6-8B40-FA44849F2B3D

P1476

Q26853619-7FF7725B-E75C-4BAE-9C21-075F6E275384

P2093

Q26853619-2595A929-555F-43A6-81AD-35387E3B16AE

Q26853619-5E1E2684-05E2-4C70-8A87-9DE32F23B485

Q26853619-7D7D5FA5-79D8-49F5-A394-B2D6C415F2A1

Q26853619-BEC42DCD-17F2-47E2-869D-C02EA0A9BDC8

Q26853619-C93F1DA5-6359-4C64-B8B5-F8D248C37057

Q26853619-FA212A00-BD7F-45B6-ADD8-A3202878AFA0

P2860

Q26853619-081A0DB9-AE0E-467F-BEEF-86BAEC4CCD6B

Q26853619-09267870-C2AC-423C-ADB8-819086D204CF

Q26853619-0ABBF557-21DE-446A-A611-B0DAB234DFCD

Q26853619-0C98096C-4016-4055-9CA1-059355B52A62

Q26853619-0F16FD3F-1ACC-44FD-A932-0273C488800E

Q26853619-16400D14-C7D4-4245-B647-FCE3C665520E

Q26853619-1E3B2C89-EA55-47B5-B412-8C723883D16F

Q26853619-20901AFB-B96F-4F4F-9CEF-1094AEBFBC60

Q26853619-21633305-C1BD-4FAC-9249-E76DDA3A12DA

Q26853619-28FECFF4-D148-476A-96E4-743C7037EF04

P304

Q26853619-62DD94F8-4D71-414E-98B4-258FA1ABDD10

P31

Q26853619-647BEDD5-42EF-407C-B96E-618B8751C144

Q26853619-DEF32FC8-72C8-4069-9CE5-703DF3804003

P356

Q26853619-02300B42-E617-45B7-BFFA-EE77860BF775

P407

Q26853619-DD21DFD1-01E1-4C21-92FC-3E664B9E4271

P433

Q26853619-D635F621-393D-4E9D-B975-AC92BF104D9A

P478

Q26853619-17352076-34F5-478E-BCA9-0422140AED26

P50

Q26853619-D4A3A62E-73AB-4697-BE7E-119729F60C2F

P577

Q26853619-3596EED3-922A-4056-9FBC-E93AB6ED1D61

P698

Q26853619-D2F50739-6A6A-42B0-BC9E-A1B18C59C5C0

P921

Q26853619-71693DBA-AD8C-4E94-9ABB-4F29AF2020AD

P932

Q26853619-96D69F47-36AC-46E3-911C-11EEB54517EA

P356

P1433

Current Oncology

P1476

Adjuvant chemotherapy for earl ...... rio systemic therapy guideline

@en

P2093

A Eisen

http://www.w3.org/2001/XMLSchema#string

M E Trudeau

http://www.w3.org/2001/XMLSchema#string

M Mates

http://www.w3.org/2001/XMLSchema#string

O C Freedman

http://www.w3.org/2001/XMLSchema#string

S F Dent

http://www.w3.org/2001/XMLSchema#string

S Gandhi

http://www.w3.org/2001/XMLSchema#string

P2860

FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial.

Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews

Meta-analysis of individual patient data from randomized trials: a review of methods used in practice.

Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.

Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer.

Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.

Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer

Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.

P304

S82-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

systematic review

P356

10.3747/CO.22.2321

http://www.w3.org/2001/XMLSchema#string

P407

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25848343

http://www.w3.org/2001/XMLSchema#string

P921

P932

4381795

http://www.w3.org/2001/XMLSchema#string